Harvard's Cancer Research Lab Faces Uncertainty as Funding Disruptions Slow Progress.
The pink-lidded jars in Joan Brugge's laboratory contain samples of breast tissue from patients, each holding the potential to unlock a new way to prevent breast cancer. With over 100 samples analyzed using high-powered microscopes and complex computer algorithms, her team has diagrammed every stage of cancer development, from initial cell mutation to tumor formation.
However, Brugge's work was severely disrupted last year when her $7 million NIH grant was frozen due to the Trump administration's handling of antisemitism on campus. The freeze, along with a ban on new federal funding for Harvard researchers, sent shockwaves through the academic community and left many employees without guaranteed salaries.
The lab lost seven employees in total, including postdocs, graduate students, and staff scientists. One former staffer has relocated to Switzerland for her PhD program, citing concerns about future visa approvals if she speaks publicly about her experience as a scientist. Another former employee took a job at a health management company, while four others pursued further education.
The uncertainty surrounding Brugge's lab highlights the challenges facing the next generation of cancer researchers in the US. With federal funding proposals under review, including a potential 40% cut to the NIH budget, the future of research hangs in the balance.
The consequences of reduced funding will be felt directly by patients, who rely on innovative treatments and new drugs developed through federally funded research. A recent study found that more than half of NIH-funded drugs approved since 2000 would not have been developed with a smaller budget.
Despite the setbacks, Brugge remains committed to her work and continues to search for new sources of funding. However, she admits that the lab's productivity has suffered as a result of the disruptions, making it difficult to focus on her goal of preventing breast cancer.
The pink-lidded jars in Joan Brugge's laboratory contain samples of breast tissue from patients, each holding the potential to unlock a new way to prevent breast cancer. With over 100 samples analyzed using high-powered microscopes and complex computer algorithms, her team has diagrammed every stage of cancer development, from initial cell mutation to tumor formation.
However, Brugge's work was severely disrupted last year when her $7 million NIH grant was frozen due to the Trump administration's handling of antisemitism on campus. The freeze, along with a ban on new federal funding for Harvard researchers, sent shockwaves through the academic community and left many employees without guaranteed salaries.
The lab lost seven employees in total, including postdocs, graduate students, and staff scientists. One former staffer has relocated to Switzerland for her PhD program, citing concerns about future visa approvals if she speaks publicly about her experience as a scientist. Another former employee took a job at a health management company, while four others pursued further education.
The uncertainty surrounding Brugge's lab highlights the challenges facing the next generation of cancer researchers in the US. With federal funding proposals under review, including a potential 40% cut to the NIH budget, the future of research hangs in the balance.
The consequences of reduced funding will be felt directly by patients, who rely on innovative treatments and new drugs developed through federally funded research. A recent study found that more than half of NIH-funded drugs approved since 2000 would not have been developed with a smaller budget.
Despite the setbacks, Brugge remains committed to her work and continues to search for new sources of funding. However, she admits that the lab's productivity has suffered as a result of the disruptions, making it difficult to focus on her goal of preventing breast cancer.